Lung Cancer Care at a Tipping Point: Advancements and Challenges

Technology, private equity, and strategic medtech partnerships are reshaping lung cancer care, bringing new innovations to the forefront of early detection and treatment.

Lung cancer remains the deadliest cancer worldwide, yet early detection rates continue to lag. While screening and diagnostic advancements hold promise, the complexity of care pathways and industry fragmentation have hindered progress. The panel discussion at LSI USA ’24 — Lung Cancer at a Tipping Point: Innovation, Private Equity, and Strategic Partnerships Driving Industry Expansion — brought together leading voices in medtech to discuss how we can drive meaningful change in lung cancer care.

The Lung Cancer Care Landscape: A Critical Need for Innovation

“Lung cancer is the biggest cancer killer, and unfortunately, it’s an incredibly aggressive disease,” said David Beylik, Partner at Ajax Health. “The only way to impact care is to catch it early.”

Despite the well-documented benefits of early detection, lung cancer screening rates remain alarmingly low. “Less than 7% of eligible patients receive low-dose CT screening each year, even though it’s reimbursed,” Beylik pointed out. In contrast, breast cancer screening compliance sits at 70%. This massive disparity represents both a challenge and an opportunity.

This blog is originally published here: https://www.lsiusasummit.com/news/lung-cancer-care-at-a-tipping-point-advancements-and-challenges